Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15845
Revised: February 22, 2014
Accepted: June 2, 2014
Published online: November 14, 2014
Processing time: 337 Days and 2.6 Hours
AIM: To compare efficacy, patient compliance, acceptability, satisfaction, safety, and adenoma detection rate of sodium phosphate tablets (NaP, CLICOLONTM) to a standard 4 L polyethylene glycol (PEG) solution for bowel cleansing for adults undergoing colonoscopy.
METHODS: In this multicenter, randomized, prospective, investigator-blind study, the relatively young (19-60 years) healthy outpatients without comorbidity were randomly assigned to one of two arms. All colonoscopy were scheduled in the morning. The NaP group was asked to take 4 tablets, 5 times the evening before and 4 tablets, 3 times early on the morning of the colonoscopy. The PEG group was asked to ingest 2 L of solution the evening before and 2 L early in the morning of the procedure. Adequacy of bowel preparation was scored using the Boston bowel preparation scale.
RESULTS: No significant differences were observed between the NaP group (n = 158) and PEG group (n = 162) in bowel cleansing quality (adequate preparation 93.0% vs 92.6%, P = 0.877), patient compliance (P = 0.228), overall adverse events (63.3% vs 69.1%, P = 0.269), or adenoma detection rate (34.8% vs 35.2%, P = 0.944). Patient acceptability, satisfaction, and patient rating of taste were higher in the NaP group than in the PEG group (P < 0.001).
CONCLUSION: NaP tablets, compared with PEG solution, produced equivalent colon cleansing, did not cause more side effects, and had better patient acceptability and satisfaction in the relatively young (age < 60 years) healthy individuals without comorbidity. An oral tablet formulation could make bowel preparation less burdensome, resulting in greater patient participation in screening programs.
Core tip: Sodium phosphate (NaP) tablets were equally efficacious as standard 4 L polyethylene glycol (PEG) solution for bowel cleansing for colonoscopy and did not results in greater side effects. Furthermore, patient acceptance and satisfaction of NaP tablets were superior to 4 L PEG solution. NaP tablets in this trial were safe, well-tolerated, and efficient for bowel preparation in the relatively young (age < 60 years) healthy individuals without comorbidity. A more acceptable oral tablet formation might provide a valuable alternative for individuals who are reluctant to undergo colonoscopy because of aversion to the currently available purgatives.